Matthew J. Ellis, MD, PhD, FRCP

Articles

This article aims to provide an overview of The Cancer Genome Atlas findings, with a particular focus on their potential biological relevance and therapeutic implications.

The Cancer Genome Atlas: Clinical Applications for Breast Cancer

It is time to develop more active treatments in the early-disease setting that actually eradicate ER-positive breast cancer before new mutations and secondary resistance have a chance to develop. In this regard, standard chemotherapy is not the answer.

The Natural History of Hormone Receptor–Positive Breast Cancer: Attempting to Decipher an Intriguing Concept

Poly(adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitors are designed to exploit the “synthetic lethality” concept for cancer therapy.

PARP Inhibitors and Their Evolving Role in Breast Cancer

Anderson et al highlight the Breast Health Global Initiative for guideline development and discuss how developments in low and middle income countries have parallels in the delivery of health care to underserved populations in industrialized countries. Guidelines for appropriate breast cancer treatment must address early detection, accurate diagnosis, and the delivery of timely and appropriate treatment modalities.

Author | Matthew J. Ellis, MD, PhD, FRCP

Articles

New content coming soon, please check back later.